Psychedelic Renaissance: LSD Re-emerges as Promising Anxiety Treatment

Views 126

In a surprising turn of events, LSD - once a symbol of 1960s counterculture - is now poised to revolutionize the treatment of anxiety disorders.

In a remarkable development, the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to MM120, an LSD-based medication for the treatment of generalized anxiety disorder (GAD).1 Developed by the biotech company MindMed, MM120 (lysergide d-tartrate) has shown impressive results in a recent Phase 2 clinical trial, offering hope for millions of people struggling with anxiety.

The trial, which involved a single dose of MM120, found that 48% of patients were in remission 12 weeks after treatment, while 65% experienced significantly improved symptoms.2 These outcomes surpassed those typically seen with current standard treatments, such as cognitive behavioral therapy, sedatives, and serotonin-modulating medications like buspirone and selective serotonin reuptake inhibitors (SSRIs).3

According to Dr. Daniel Karlin, MindMed's chief medical officer and assistant professor of psychiatry at Tufts University School of Medicine, "The clinical improvement for many patients was more than double what we see with today's standard of care. This occurred at all levels of anxiety, from moderate all the way up to severe."4 Notably, MM120 was administered as a single tablet dissolved on the tongue under supervision, without the need for concurrent psychotherapy.5

The study marks the first time a single dose of LSD has been shown to effectively treat GAD without adjunctive psychotherapy, as noted by Gabriella Gobbi, a psychedelics researcher at McGill University who was not involved in the trial.6 This groundbreaking finding challenges the prevailing view that psychedelic-assisted therapy requires the integration of psychotherapy to be effective.

The FDA's breakthrough therapy designation is granted to expedite the development and review of drugs that treat serious or life-threatening conditions and demonstrate substantial improvement over available therapies based on preliminary clinical evidence.7 This designation is expected to attract significant investment for MindMed, with the company anticipating an influx of $175 million.8

MindMed plans to commence Phase 3 clinical trials before the end of the year, bringing MM120 one step closer to potential FDA approval and widespread availability.9 If successful, this innovative treatment could transform the lives of the millions of people worldwide who suffer from GAD, offering rapid, long-lasting relief with fewer side effects and a more streamlined treatment process compared to current options.

The re-emergence of LSD as a promising therapeutic agent marks a significant shift in the perception of psychedelics, from stigmatized substances to potential breakthrough treatments for mental health disorders. As research continues to uncover the therapeutic potential of these compounds, it is crucial to approach their use with caution, ensuring proper medical supervision and adherence to regulatory guidelines.

In conclusion, the FDA's breakthrough therapy designation for MindMed's MM120 represents a major milestone in the development of novel treatments for anxiety disorders. As the company progresses through Phase 3 trials, the medical community and those affected by GAD await the results with hope and anticipation, eager to witness the potential dawn of a new era in mental health treatment.

To learn more about natural approaches to anxiety, visit our database on the subject here.

To learn more about natural approaches to depression, visit our database on the subject here.

To learn more about the research on LSD's therapeutic potential visit our database on the subject here.


1. Dier, A. (2024, March 9). FDA: LSD is now a breakthrough therapy. Newser. Retrieved from

2. Ibid.

3. Ibid.

4. Ibid.

5. Ibid.

6. Ibid.

7. Ibid.

8. Ibid.

9. Ibid.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of GreenMedInfo or its staff.

Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024, Journal Articles copyright of original owners, MeSH copyright NLM.